Connect
MJA
MJA

Management of adverse events related to new cancer immunotherapy (immune checkpoint inhibitors)

Rose Liu, Pablo Fernandez-Peñas and Deshan F Sebaratnam
Med J Aust 2017; 206 (9): 412. || doi: 10.5694/mja16.01357
Published online: 15 May 2017

The well researched narrative review by Bourke and colleagues1 offers a comprehensive overview of immune-related adverse events (irAEs) in cancer immunotherapy and their management. However, care needs to be taken in adopting too broad an approach, particularly in relation to dermatological irAEs.

  • Rose Liu1,2
  • Pablo Fernandez-Peñas2,3
  • Deshan F Sebaratnam2,4

  • 1 Royal Prince Alfred Hospital, Sydney, NSW
  • 2 Westmead Hospital, Sydney, NSW
  • 3 University of Sydney, Sydney, NSW
  • 4 Skin and Cancer Foundation Australia, Sydney, NSW

Correspondence: d.sebaratnam@hotmail.com

Competing interests:

No relevant disclosures.

Author

remove_circle_outline Delete Author
add_circle_outline Add Author

Comment
Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.